KR830004849A - Method of Preparation of Pharmaceutical Formulations - Google Patents

Method of Preparation of Pharmaceutical Formulations Download PDF

Info

Publication number
KR830004849A
KR830004849A KR1019810001029A KR810001029A KR830004849A KR 830004849 A KR830004849 A KR 830004849A KR 1019810001029 A KR1019810001029 A KR 1019810001029A KR 810001029 A KR810001029 A KR 810001029A KR 830004849 A KR830004849 A KR 830004849A
Authority
KR
South Korea
Prior art keywords
cisplatin
solvent medium
solution
preparation
molecular weight
Prior art date
Application number
KR1019810001029A
Other languages
Korean (ko)
Other versions
KR860000841B1 (en
Inventor
아더 카프란 무레이
피터 그라나텍 알폰서
Original Assignee
도미닉엠. 메자펠레
브리스톨 마이어스 캄페니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도미닉엠. 메자펠레, 브리스톨 마이어스 캄페니 filed Critical 도미닉엠. 메자펠레
Publication of KR830004849A publication Critical patent/KR830004849A/en
Application granted granted Critical
Publication of KR860000841B1 publication Critical patent/KR860000841B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음No content

Description

약학적 제제의 제조방법Method of Preparation of Pharmaceutical Formulations

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (1)

용매 매체에서 시스프타린의 충분한양을 용해시켜 2.5내지 25mg/ml의 시스프라틴농도를 제공하며 언급한 용매매체는 평균분자량 150 내지 9000을 갖는 30% 내지 약 95% 폴리에틸렌글리콜 또는 평균분자량 300내지 6000을 갖는 매톡시플티에틸렌글리콜 또는 이들의 혼합물, 과 5%내지 70%물로 구성되며 언급한 용액은 용액에서 존재하는 시스프라틴의 양에대해 적어도 당량의 비독성 약학적으로 받아들여질 수 있는 염소이온을 포함하는 것으로 구성되는 용매매체에서 시스프라틴의 안정농축된 용액을 제조하는 방법.Dissolving a sufficient amount of cisphthalin in the solvent medium provides a cisplatin concentration of 2.5 to 25 mg / ml and the solvent medium mentioned is 30% to about 95% polyethylene glycol or an average molecular weight of 300 to having an average molecular weight of 150 to 9000. Methoxypolyethyleneglycol having 6000 or mixtures thereof, and 5% to 70% water and the solution mentioned comprises at least an equivalent nontoxic pharmaceutically acceptable chlorine relative to the amount of cisplatin present in the solution. A method for preparing a stable concentrated solution of cisplatin in a solvent medium comprising ions. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019810001029A 1980-03-31 1981-03-28 Process of preparing stable concentrated solutions of cisplatin KR860000841B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13537380A 1980-03-31 1980-03-31
US135.373 1980-03-31
US135373 1980-03-31

Publications (2)

Publication Number Publication Date
KR830004849A true KR830004849A (en) 1983-07-20
KR860000841B1 KR860000841B1 (en) 1986-07-09

Family

ID=22467813

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019810001029A KR860000841B1 (en) 1980-03-31 1981-03-28 Process of preparing stable concentrated solutions of cisplatin

Country Status (30)

Country Link
JP (1) JPS56152415A (en)
KR (1) KR860000841B1 (en)
AR (1) AR225500A1 (en)
AT (1) AT370996B (en)
AU (1) AU541056B2 (en)
BE (1) BE888209A (en)
CA (1) CA1162479A (en)
CH (1) CH647481A5 (en)
CS (1) CS246051B2 (en)
DD (1) DD157762A5 (en)
DE (1) DE3112272A1 (en)
DK (1) DK158564C (en)
ES (1) ES500869A0 (en)
FI (1) FI70670C (en)
FR (1) FR2480605A1 (en)
GB (1) GB2074028B (en)
GR (1) GR72769B (en)
HU (1) HU183379B (en)
IE (1) IE51070B1 (en)
IL (1) IL62517A (en)
IT (1) IT1170838B (en)
LU (1) LU83270A1 (en)
NL (1) NL8101531A (en)
NO (1) NO156675C (en)
NZ (1) NZ196519A (en)
PH (1) PH17152A (en)
PT (1) PT72774B (en)
SE (1) SE455045B (en)
SU (1) SU1056893A3 (en)
ZA (1) ZA812084B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1153974B (en) * 1982-09-23 1987-01-21 Erba Farmitalia PHARMACOLOGICAL COMPOSITIONS BASED ON CISPLATIN AND METHOD FOR THEIR OBTAINMENT
NL8303657A (en) * 1983-10-24 1985-05-17 Pharmachemie Bv SOLUTION, STABLE, AQUEOUS, AQUEOUS, CONTAINING SOLUTION OF CISPLATINE, AND METHOD OF PREPARING THEREOF.
FI895340A0 (en) * 1988-11-14 1989-11-09 Bristol Myers Squibb Co HYPERTONISK CISPLATIN-LOESNING.
ES2208946T3 (en) * 1996-08-23 2004-06-16 Sequus Pharmaceuticals, Inc. LIPOSOMES CONTAINING A CISPLATIN COMPOUND.
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
JP4445304B2 (en) 2004-03-26 2010-04-07 オンキヨー株式会社 Switching amplifier
US8852566B2 (en) * 2009-03-26 2014-10-07 Warsaw Orthopedic, Inc. Compositions and methods for preferential distribution of active agents to injury sites
US11752135B2 (en) 2018-03-29 2023-09-12 Project Pharmaceutics Gmbh Liquid pharmaceutical formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) * 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
CA1119954A (en) * 1978-05-30 1982-03-16 Edmund S. Granatek Aqueous solution of cisplatin

Also Published As

Publication number Publication date
ATA150481A (en) 1982-10-15
IL62517A0 (en) 1981-05-20
ZA812084B (en) 1982-04-28
DD157762A5 (en) 1982-12-08
GB2074028A (en) 1981-10-28
AR225500A1 (en) 1982-03-31
AU6816681A (en) 1981-10-08
GB2074028B (en) 1983-09-21
IT1170838B (en) 1987-06-03
LU83270A1 (en) 1981-10-29
NO156675C (en) 1987-11-04
NO156675B (en) 1987-07-27
IE51070B1 (en) 1986-09-17
IL62517A (en) 1984-01-31
DE3112272C2 (en) 1990-09-27
IE810715L (en) 1981-09-30
IT8148090A0 (en) 1981-03-24
AU541056B2 (en) 1984-12-13
PH17152A (en) 1984-06-13
FR2480605A1 (en) 1981-10-23
DE3112272A1 (en) 1982-04-29
AT370996B (en) 1983-05-25
ES8206545A1 (en) 1982-08-16
CA1162479A (en) 1984-02-21
NO811081L (en) 1981-10-01
DK158564B (en) 1990-06-11
KR860000841B1 (en) 1986-07-09
FR2480605B1 (en) 1984-05-11
PT72774A (en) 1981-04-01
NL8101531A (en) 1981-10-16
CS246051B2 (en) 1986-10-16
HU183379B (en) 1984-04-28
FI70670C (en) 1986-10-06
SU1056893A3 (en) 1983-11-23
ES500869A0 (en) 1982-08-16
JPS6360008B2 (en) 1988-11-22
BE888209A (en) 1981-09-30
PT72774B (en) 1982-11-16
FI70670B (en) 1986-06-26
DK144281A (en) 1981-10-01
DK158564C (en) 1990-11-05
JPS56152415A (en) 1981-11-26
GR72769B (en) 1983-12-02
SE455045B (en) 1988-06-20
SE8101990L (en) 1981-11-13
CH647481A5 (en) 1985-01-31
FI810934L (en) 1981-10-01
NZ196519A (en) 1983-06-17

Similar Documents

Publication Publication Date Title
KR850700216A (en) Method for dissolving the active ingredient and pharmaceutical composition obtained therefrom
SE7903817L (en) MORANOLIN DERIVATIVES
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
KR830002327A (en) Pharmaceutical preparations
KR840002650A (en) Pharmaceutical Compositions Containing Ubidecarenone
JPS51148013A (en) Stable insulin preparation for nosal administration
KR860000865A (en) Preparation of Pharmaceutical Formulations
KR830004849A (en) Method of Preparation of Pharmaceutical Formulations
KR910005878A (en) Stable solution of mitomycin C
KR870001830A (en) Process for producing high temperature melt terpenadine composition
KR880007060A (en) Pharmaceutical composition
FR2548676B1 (en) BIOPOLYMER COMPOSITIONS AND THEIR PREPARATION PROCESS
ATE65395T1 (en) ACETYLCYSTEINE CONTAINING SOLID WATER-SOLUBLE MEDICINAL PRODUCT.
KR910005846A (en) Toothpaste composition
KR910005869A (en) Stable, injectable pharmaceutical compositions for anti-neoplastic compounds having at least one ethyleneimine group and methods for their preparation
PT893121E (en) MEDICINAL LIQUID ORAL SOLUTION
JPS5750914A (en) Betamethasone external pharmaceutical
KR850006136A (en) Etoposide Oral Dosage Form
ATE1442T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ALL-E- OR 13-Z-7,8-DEHYDRO-RETINOIC ACID AND PROCESS FOR ITS PREPARATION.
JPS5437154A (en) Antistatic polyester composition
ES464706A1 (en) Storage stable valerian extracts - obtd. by dehydration of conventional valerian extracts
JPS5726587A (en) Stabilization of ascorbic acid oxidase
KR880001293A (en) Combination of active substances with antithrombin action
NO893505D0 (en) PROCEDURE FOR THE PREPARATION OF PHOTO TEROLS OR DERIVATIVES THEREOF WITH IMPROVED WATER SOLUBILITY.
SE8206728D0 (en) LEKEMEDELSPREPARAT